{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 45,
        "end": 56
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 71,
        "end": 75
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 107,
        "end": 113
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 119,
        "end": 130
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 148,
        "end": 179
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 148,
        "end": 156
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22521649_12",
  "text": "CONCLUSIONS : Our current data indicate that lung cancer patients with EGFR -mutations had longer PFS with taxane than gemcitabine when receiving a platinum -based doublet regimen ."
}
